Considerations when prescribing opioid agonist therapies for people living with HIV

References

• Fauci AS, Redfield RR, Sigounas G, et al. Ending the HIV epidemic: a plan for the United States. JAMA. 2019;321(9):844–845. doi: 10.1001/jama.2019.1343
   PubMed Web of Science ®Google Scholar
• Singer M, Bulled N, Ostrach B, et al. Syndemics and the biosocial conception of health. Lancet. 2017;389(10072):941–950. doi: 10.1016/S0140-6736(17)30003-X
   PubMed Web of Science ®Google Scholar
• Des Jarlais DC, Kerr T, Carrieri P, et al. HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks. AIDS. 2016 Mar 27;30(6):815–826. doi: 10.1097/QAD.0000000000001039
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wilson TE, Adedimeji A, et al. The impact of substance use on adherence to antiretroviral therapy among HIV-infected women in the United States. AIDS & Behav. 2018;22(3):896–908. doi: 10.1007/s10461-017-1808-4
   PubMed Web of Science ®Google Scholar
• Strathdee SA, Kuo I, El-Bassel N, et al. Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même chose. AIDS. 2020 Nov 15;34(14):1997–2005. doi: 10.1097/QAD.0000000000002673
   PubMed Web of Science ®Google Scholar
• Springer SA, Merluzzi AP, Del Rio C. Integrating responses to the opioid use disorder and infectious disease epidemics: a report from the national academies of sciences, engineering, and medicine. JAMA. 2020;324(1):37–38. doi: 10.1001/jama.2020.2559
   PubMed Web of Science ®Google Scholar
• Springer SA, Barocas JA, Wurcel A, et al. Federal and state action needed to end the infectious complications of illicit drug use in the United States: IDSA and HIVMA’s advocacy agenda. J Infect Dis. 2020;222(Supplement_5):S230–S238. doi: 10.1093/infdis/jiz673
   PubMedGoogle Scholar
• Gandhi RT, Bedimo R, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society–USA panel. JAMA. 2023;329(1):63–84. doi: 10.1001/jama.2022.22246
   PubMed Web of Science ®Google Scholar
• MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. Br Med J. 2012;345(oct03 3):e5945. doi: 10.1136/bmj.e5945
   PubMedGoogle Scholar
• Lier AJ, Seval N, Vander Wyk B, et al. Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder. J Subst Abuse Treat. 2022 Nov;142:108852. doi: 10.1016/j.jsat.2022.108852
   PubMed Web of Science ®Google Scholar
• Lee JD, Nunes EV Jr., Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018 Jan 27;391(10118):309–318. doi: 10.1016/S0140-6736(17)32812-X
   PubMed Web of Science ®Google Scholar
• Springer SA, Di Paola A, Azar MM, et al. Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results of a double-blind, placebo-controlled randomized trial. J Acquir Immune Defic Syndr. 2018 May 1;78(1):43–53. doi: 10.1097/QAI.0000000000001634
   PubMed Web of Science ®Google Scholar
• Jarvis BP, Holtyn AF, Subramaniam S, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018 Jul;113(7):1188–1209. doi: 10.1111/add.14180
   PubMed Web of Science ®Google Scholar
• Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the international AIDS society-USA panel. JAMA. 2010 Jul;304(3):321–333. doi: 10.1001/jama.2010.1004
   PubMed Web of Science ®Google Scholar
• Uhlmann S, Milloy MJ, Kerr T, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction. 2010;105(5):907–913. doi: 10.1111/j.1360-0443.2010.02905.x
   PubMed Web of Science ®Google Scholar
• Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011 Mar 1;56(Suppl 1):S22–32. doi: 10.1097/QAI.0b013e318209751e
   PubMed Web of Science ®Google Scholar
• Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health. 2010 Jul;87(4):592–602. doi: 10.1007/s11524-010-9438-4
   PubMed Web of Science ®Google Scholar
• Springer SA, Qiu J, Saber-Tehrani AS, et al. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLOS ONE. 2012;7(5):e38335. doi: 10.1371/journal.pone.0038335
   PubMed Web of Science ®Google Scholar
• SocíSocíAs ME, Wood E, Small W, et al. Methadone maintenance therapy and viral suppression among HIV-infected opioid users: the impacts of crack and injection cocaine use. Drug Alcohol Depend. 2016 Nov 01;168:211–218. doi: 10.1016/j.drugalcdep.2016.09.013
   PubMed Web of Science ®Google Scholar
• Alanis-Hirsch K, Croff R, Ford JH, et al. Extended-release naltrexone: a qualitative analysis of barriers to routine use. J Subst Abuse Treat. 2016 Mar 01;62:68–73. doi: 10.1016/j.jsat.2015.10.003
   PubMed Web of Science ®Google Scholar
• Duffy M, Ghosh A, Geltman A, et al. Coordinating systems of care for HIV and opioid use disorder: a systematic review of enablers and barriers to integrated service access, and systems and tools required for implementation. Med Care Res Rev. 2022 Oct;79(5):618–639. doi: 10.1177/10775587211051182
   PubMed Web of Science ®Google Scholar
• Springer SA. Ending the HIV epidemic for persons who use drugs: the practical challenges of meeting people where they are. J Gen Intern Med. 2023 Sep 01;38(12):2816–2818. doi: 10.1007/s11606-023-08142-2
   PubMed Web of Science ®Google Scholar
• Taylor AMW, Becker S, Schweinhardt P, et al. Mesolimbic dopamine signaling in acute and chronic pain: implications for motivation, analgesia, and addiction. Pain. 2016 Jun;157(6):1194–1198. doi: 10.1097/j.pain.0000000000000494
   PubMed Web of Science ®Google Scholar
• Boom M, Niesters M, Sarton E, et al. Non-analgesic effects of opioids: opioid-induced respiratory depression. Curr Pharm Des. 2012;18(37):5994–6004. doi: 10.2174/138161212803582469
   PubMed Web of Science ®Google Scholar
• Merlin JS. Chronic pain in patients with HIV infection: what clinicians need to know. Top Antivir Med. 2015 Aug;23(3):120–124.
   PubMedGoogle Scholar
• Tsao JC, Plankey MW, Young MA. Pain, psychological symptoms and prescription drug misuse in HIV: a literature review. J Pain Manag. 2012 Apr;5(2):111–118.
   PubMedGoogle Scholar
• Cunningham CO. Opioids and HIV infection: from pain management to addiction treatment. Topics Anti Med. 2018;25(4):143.
   PubMedGoogle Scholar
• Edelman EJ, Gordon K, Becker WC, et al. Receipt of opioid analgesics by HIV-infected and uninfected patients. J Gen Intern Med. 2013 Jan;28(1):82–90. doi: 10.1007/s11606-012-2189-z
   PubMed Web of Science ®Google Scholar
• Behar E, Bagnulo R, Knight K, et al. “Chasing the pain relief, not the high”: experiences managing pain after opioid reductions among patients with HIV and a history of substance use. PLOS ONE. 2020;15(3):e0230408. doi: 10.1371/journal.pone.0230408
   PubMed Web of Science ®Google Scholar
• Hoots BE, Xu L, Kariisa M, et al. Annual surveillance report of drug-related risks and outcomes–United States. 2018.
   Google Scholar
• Scholl L, Seth P, Kariisa M, et al. Drug and opioid-involved overdose deaths—United States, 2013–2017. Morbidity Mortality Weekly Rep. 2019;67(51–52):1419. doi: 10.15585/mmwr.mm6751521e1
   Web of Science ®Google Scholar
• Prevention CfDCa. Drug overdose death data 2023. Available from: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
   Google Scholar
• Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344–350. doi: 10.1097/YCO.0000000000000717
   PubMed Web of Science ®Google Scholar
• Friedman J, Shover CL. Charting the fourth wave: geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010–2021. Addiction. 2023 Dec 01;118(12):2477–2485. doi: 10.1111/add.16318
   PubMed Web of Science ®Google Scholar
• Administration SAa MHS. Key substance use and mental health indicators in the United States: results from the 2022. National Survey on Drug Use and Health (HHS Publication No. PEP23-07-01-006, NSDUH Series H-58). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. 2023.
   Google Scholar
• Tsui JI, Akosile MA, Lapham GT, et al. Prevalence and medication treatment of opioid use disorder among primary care patients with hepatitis C and HIV. J Gen Intern Med. 2021 Apr;36(4):930–937. doi: 10.1007/s11606-020-06389-7
   PubMed Web of Science ®Google Scholar
• Strathdee SA, Beyrer C. Threading the needle—how to stop the HIV outbreak in rural Indiana. N Engl J Med. 2015;373(5):397–399. doi: 10.1056/NEJMp1507252
   PubMed Web of Science ®Google Scholar
• Ogden SN, Harris MTH, Childs E, et al. “You need money to get high, and that’s the easiest and fastest way:” a typology of sex work and health behaviours among people who inject drugs. Int J Drug Policy. 2021 Oct 01;96:103285. doi: 10.1016/j.drugpo.2021.103285
   PubMed Web of Science ®Google Scholar
• Saitz R. Terminology and conceptualization of opioid use disorder and implications for treatment. In: Kelly J Wakeman S, editors. Treating opioid addiction. Cham: Springer International Publishing; 2019. p. 79–87.
   Google Scholar
• Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010 Jan;35(1):217–238. doi: 10.1038/npp.2009.110
   PubMed Web of Science ®Google Scholar
• Jani C, Patel K, Walker A, et al. Trends of HIV mortality between 2001 and 2018: an observational analysis. Trop Med Infect Dis. 2021. 6(4):173. doi: 10.3390/tropicalmed6040173
   PubMedGoogle Scholar
• Stover MW, Davis JM. Opioids in pregnancy and neonatal abstinence syndrome. Semin Perinatol. 2015 Nov 01;39(7):561–565. doi: 10.1053/j.semperi.2015.08.013
   PubMed Web of Science ®Google Scholar
• Blondin D, Crawford RI, Kerr T, et al. Dermatologic manifestations of underlying infectious disease among illicit injection-drug users. J Cutan Med Surg. 2008;12(2):71–76. doi: 10.2310/7750.2008.06165
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC); 2013.
   Google Scholar
• Matson TE, Hallgren KA, Lapham GT, et al. Psychometric performance of a substance use symptom checklist to help clinicians assess substance use disorder in primary care. JAMA Netw Open. 2023;6(5):e2316283. doi: 10.1001/jamanetworkopen.2023.16283
   PubMed Web of Science ®Google Scholar
• Oga EA, Mark K, Peters EN, et al. Validation of the NIDA-modified ASSIST as a screening tool for prenatal drug use in an urban setting in the United States. J Addict Med. 2020 Sep;14(5):423–430. doi: 10.1097/ADM.0000000000000614
   PubMed Web of Science ®Google Scholar
• Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the drug abuse screening test. J Subst Abuse Treat. 2007;32(2):189–198. doi: 10.1016/j.jsat.2006.08.002
   PubMed Web of Science ®Google Scholar
• McNeely J, Strauss SM, Saitz R, et al. A brief patient self-administered substance use screening tool for primary care: two-site validation study of the substance use brief screen (SUBS). Am J Med. 2015;128(7):784–e9. doi: 10.1016/j.amjmed.2015.02.007
   Web of Science ®Google Scholar
• McNeely J, Wu L-T, Subramaniam G, et al. Performance of the tobacco, alcohol, prescription medication, and other substance use (TAPS) tool for substance use screening in primary care patients. Ann Intern Med. 2016 Nov 15;165(10):690–699. doi: 10.7326/M16-0317
   PubMed Web of Science ®Google Scholar
• Knight K, Simpson DD, Morey JT. An evaluation of the TCU drug screen. Washington (DC): National Institute of Justice, Office of Justice Programs, US Department of Justice; 2002.
   Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, et al. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33.
   PubMed Web of Science ®Google Scholar
• Wickersham JA, Azar MM, Cannon CM, et al. Validation of a brief measure of opioid dependence: the rapid opioid dependence screen (RODS). J Correct Health Care. 2015 Jan;21(1):12–26. doi: 10.1177/1078345814557513
   PubMed Web of Science ®Google Scholar
• Di Paola A, Farabee D, Springer SA. Validation of two diagnostic assessments for opioid and stimulant use disorder for use by non‐clinicians. Psychiatric Res And Clin Pract. 2023;5(3):78–83. doi: 10.1176/appi.prcp.20230022
   PubMedGoogle Scholar
• Judd H, Yaugher AC, O’Shay S, et al. Understanding stigma through the lived experiences of people with opioid use disorder. Drug Alcohol Depend. 2023 Aug 01;249:110873. doi: 10.1016/j.drugalcdep.2023.110873
   PubMed Web of Science ®Google Scholar
• Brooks R, Wegener M, Freeman B, et al. Improving HIV and HCV testing in substance use disorder programs (SUDs) that provide medications for opiate use disorder (MOUD): role of addressing barriers and implementing universal and site-specific approaches. Health Promot Pract. 2023;24(5):1018–1028. doi: 10.1177/15248399231169791
   PubMed Web of Science ®Google Scholar
• Ni Z, Altice FL, Wickersham JA, et al. Willingness to initiate pre-exposure prophylaxis (PrEP) and its use among opioid-dependent individuals in drug treatment. Drug Alcohol Depend. 2021 Feb 01;219:108477. doi: 10.1016/j.drugalcdep.2020.108477
   PubMed Web of Science ®Google Scholar
• McNamara KF, Biondi BE, Hernández-Ramírez RU, et al. A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes. Open Forum Infect Dis. 2021;8(8):ofab289. doi: 10.1093/ofid/ofab289
   PubMed Web of Science ®Google Scholar
• Low AJ, Mburu G, Welton NJ, et al. Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis. Clinical Infectious Diseases. 2016;63(8):1094–1104. doi: 10.1093/cid/ciw416
   PubMed Web of Science ®Google Scholar
• Tanum L, Solli KK, Latif ZE, et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry. 2017 Dec 1;74(12):1197–1205. doi: 10.1001/jamapsychiatry.2017.3206
   PubMed Web of Science ®Google Scholar
• Petrakis I, Springer SA, Davis C, et al. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addict Sci Clin Pract. 2022 Jan 31;17(1):6. doi: 10.1186/s13722-022-00286-6
   PubMed Web of Science ®Google Scholar
• Waddell EN, Springer SA, Marsch LA, et al. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). J Subst Abuse Treat. 2021 Sep;128:108389. doi: 10.1016/j.jsat.2021.108389
   PubMed Web of Science ®Google Scholar
• Gordon MS, Mitchell SG, Blue TR, et al. A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail. J Subst Abuse Treat. 2021;128:108241. doi: 10.1016/j.jsat.2020.108241
   PubMed Web of Science ®Google Scholar
• Santo T Jr., Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021 Sep 1;78(9):979–993. doi: 10.1001/jamapsychiatry.2021.0976
   PubMed Web of Science ®Google Scholar
• Biondi BE, Mohanty S, Wyk BV, et al. Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder. Contemp Clin Trials Commun. 2021 Mar 01;21:100704. doi: 10.1016/j.conctc.2021.100704
   PubMed Web of Science ®Google Scholar
• Marsden J, Tai B, Ali R, et al. Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective? Addiction. 2019 Aug;114(8):1346–1353. doi: 10.1111/add.14546
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann internal med. 2018;169(3):137–145. doi: 10.7326/M17-3107
   PubMed Web of Science ®Google Scholar
• Hansen H, Siegel C, Wanderling J, et al. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Drug Alcohol Dependence. 2016;164:14–21. doi: 10.1016/j.drugalcdep.2016.03.028
   PubMed Web of Science ®Google Scholar
• Bradford D, Parman M, Levy S, et al. HIV and addiction services for people who inject drugs: healthcare provider perceptions on integrated care in the U.S. South J Prim Care Community Health. 2023 Jan;14:21501319231161208. doi: 10.1177/21501319231161208
   Web of Science ®Google Scholar
• Dunn KE, Brooner RK, Stoller KB. Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic. J Subst Abuse Treat. 2021 Feb;121:108197. doi: 10.1016/j.jsat.2020.108197
   PubMed Web of Science ®Google Scholar
• Gourevitch MN, Hartel D, Tenore P, et al. Three oral formulations of methadone: a clinical and pharmacodynamic comparison. J Subst Abuse Treat. 1999 Oct 01;17(3):237–241. doi: 10.1016/S0740-5472(99)00008-2
   PubMed Web of Science ®Google Scholar
• Ferrari A, Coccia CPR, Bertolini A, et al. Methadone—metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004 Dec 01;50(6):551–559. doi: 10.1016/j.phrs.2004.05.002
   PubMed Web of Science ®Google Scholar
• Joudrey PJ, Edelman EJ, Wang EA. Drive times to opioid treatment programs in urban and rural counties in 5 US states. JAMA. [2019 Oct 1];322(13):1310–1312. doi: 10.1001/jama.2019.12562
   PubMed Web of Science ®Google Scholar
• Baillieu R. Medications for the treatment of opioid use disorder. In: DoHaH S, editor. Federal Register. Rockville, MD: Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services (DHHS); 2024. p. 7528–7563. https://www.federalregister.gov/documents/2024/02/02/2024-01693/medications-for-the-treatment-of-opioid-use-disorder
   Google Scholar
• Cunningham C, Edlund MJ, Fishman M, et al. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. J Addict Med. 2020;14(2S):1–91.
   Google Scholar
• Buresh M, Nahvi S, Steiger S, et al. Adapting methadone inductions to the fentanyl era. J Subst Abuse Treat. 2022 Oct 01;141:108832. doi: 10.1016/j.jsat.2022.108832
   PubMed Web of Science ®Google Scholar
• Huang C-L, Tsai IJ, Lin W-C, et al. Reduced mortality in patients with extended duration of methadone maintenance treatment: a five-year retrospective nationwide study. Psychol Med. 2023;53(3):722–730. doi: 10.1017/S0033291721002051
   PubMed Web of Science ®Google Scholar
• Gourevitch MN, Friedland GH. Interactions between methadone and medications used to treat HIV infection: a review. Mt Sinai J Med. 2000;67(5–6):429–436.
   PubMedGoogle Scholar
• Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol. 2001 Mar;51(3):213–217. doi: 10.1046/j.1365-2125.2001.00342.x
   PubMed Web of Science ®Google Scholar
• Clarke SM, Mulcahy FM, Tjia J, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clinical Infectious Diseases. 2001;33(9):1595–1597. doi: 10.1086/322519
   PubMed Web of Science ®Google Scholar
• Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS. 1999;13(8):957–962. doi: 10.1097/00002030-199905280-00012
   PubMed Web of Science ®Google Scholar
• Berenguer J, Pérez- ElíElíAs MJ, Bellón JM, et al. Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort. J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):154–159. doi: 10.1097/01.qai.0000194231.08207.8a
   PubMed Web of Science ®Google Scholar
• Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clinical Infectious Diseases. 2000;30(Supplement_2):S96–S116. doi: 10.1086/313859
   PubMedGoogle Scholar
• McCance‐Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010;19(1):4–16. doi: 10.1111/j.1521-0391.2009.00005.x
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Moody DE, Smith PF, et al. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clinical Infectious Diseases. 2006;43(Supplement_4):S235–S246. doi: 10.1086/508188
   PubMedGoogle Scholar
• Taylor JL, Laks J, Christine PJ, et al. Bridge clinic implementation of “72-hour rule” methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care. Drug Alcohol Depend. 2022 Jul 01;236:109497. doi: 10.1016/j.drugalcdep.2022.109497
   PubMed Web of Science ®Google Scholar
• (SAMHSA) SAaMHA. TIP 63: medications for opioid use disorder2021. https://store.samhsa.gov/sites/default/files/pep21-02-01-002.pdf
   Google Scholar
• Maxwell S, Shinderman M. Optimizing response to methadone maintenance treatment: use of higher-dose methadone. J Psychoactive Drugs. 1999 Apr;31(2):95–102. doi: 10.1080/02791072.1999.10471730
   PubMed Web of Science ®Google Scholar
• Walley AY, Cheng DM, Pierce CE, et al. Methadone dose, take home status and hospital admission among methadone maintenance patients. J Addict Med. 2012;6(3):186. doi: 10.1097/ADM.0b013e3182584772
   PubMed Web of Science ®Google Scholar
• Chua KP, Bicket MC, Bohnert ASB, et al. Buprenorphine dispensing after elimination of the waiver requirement. N Engl J Med. 2024 Apr 25;390(16):1530–1532. doi: 10.1056/NEJMc2312906
   PubMed Web of Science ®Google Scholar
• Walsh SL, Nuzzo PA, Babalonis S, et al. Intranasal buprenorphine alone and in combination with naloxone: abuse liability and reinforcing efficacy in physically dependent opioid abusers. Drug Alcohol Dependence. 2016;162:190–198. doi: 10.1016/j.drugalcdep.2016.03.005
   PubMed Web of Science ®Google Scholar
• Shulman M, Wai JM, Nunes EV. Buprenorphine treatment for opioid use disorder: an overview. CNS Drugs. 2019 Jun;33(6):567–580. doi: 10.1007/s40263-019-00637-z
   PubMed Web of Science ®Google Scholar
• Mariani JJ, Mahony AL, Podell SC, et al. Open-label trial of a single-day induction onto buprenorphine extended-release injection for users of heroin and fentanyl. Am J Addict. 2021 Sep;30(5):470–476. doi: 10.1111/ajad.13193
   PubMed Web of Science ®Google Scholar
• Seval N, Frank CA, Litwin AH, et al. Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder. Contemp Clin Trials. 2021 Jun;105:106394. doi: 10.1016/j.cct.2021.106394
   PubMed Web of Science ®Google Scholar
• Weimer MB, Herring AA, Kawasaki SS, et al. ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids. J Addict Med. 2023;17(6):632–639. doi: 10.1097/ADM.0000000000001202
   PubMed Web of Science ®Google Scholar
• Moe J, O’Sullivan F, Hohl CM, et al. Short communication: systematic review on effectiveness of micro-induction approaches to buprenorphine initiation. Addict Behav. 2021 Mar 01;114:106740. doi: 10.1016/j.addbeh.2020.106740
   PubMed Web of Science ®Google Scholar
• Herring AA, Vosooghi AA, Luftig J, et al. High-dose buprenorphine induction in the emergency department for treatment of opioid use disorder. JAMA Netw Open. 2021;4(7):e2117128–e2117128. doi: 10.1001/jamanetworkopen.2021.17128
   PubMed Web of Science ®Google Scholar
• Wong JSH, Nikoo M, Westenberg JN, et al. Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial. Addict Sci Clin Pract. 2021 Feb 12;16(1):11. doi: 10.1186/s13722-021-00220-2
   PubMed Web of Science ®Google Scholar
• Harris E. Extended-release buprenorphine receives FDA green light. JAMA. 2023;329(24):2119–2119. doi: 10.1001/jama.2023.9929
   Web of Science ®Google Scholar
• Kampman K, Jarvis M. American society of addiction medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358. doi: 10.1097/ADM.0000000000000166
   PubMed Web of Science ®Google Scholar
• Tompkins DA, Bigelow GE, Harrison JA, et al. Concurrent validation of the clinical opiate withdrawal scale (COWS) and single-item indices against the clinical institute narcotic assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend. 2009 Nov 1;105(1–2):154–159. doi: 10.1016/j.drugalcdep.2009.07.001
   PubMed Web of Science ®Google Scholar
• Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs. 2003 Apr;35(2):253–259. doi: 10.1080/02791072.2003.10400007
   PubMed Web of Science ®Google Scholar
• Mannelli P, S Peindl K, Lee T, et al. Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives. Curr Drug Abuse Rev. 2012;5(1):52–63. doi: 10.2174/1874473711205010052
   PubMedGoogle Scholar
• Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med. 2018;178(6):764–773. doi: 10.1001/jamainternmed.2018.1052
   PubMed Web of Science ®Google Scholar
• Petrakis I, Springer SA, Davis C, et al. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addict Sci Clin Pract. 2022 Jan 31;17(1):6. doi: 10.1186/s13722-022-00286-6
   PubMed Web of Science ®Google Scholar
• Bruce RD, Moody DE, Altice FL, et al. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol. 2013 May;6(3):249–269. doi: 10.1586/ecp.13.18
   PubMed Web of Science ®Google Scholar
• Pinto RM, Chen Y, Park S. A client-centered relational framework on barriers to the integration of HIV and substance use services: a systematic review. Harm Reduct J. 2019 Dec 19;16(1):71. doi: 10.1186/s12954-019-0347-x
   PubMed Web of Science ®Google Scholar
• Des Jarlais DC, Nugent A, Solberg A, et al. Syringe service programs for persons who inject drugs in urban, suburban, and rural areas—United States, 2013. Morb Mortal Wkly Rep. 2015;64(48):1337–1341. doi: 10.15585/mmwr.mm6448a3
   PubMed Web of Science ®Google Scholar
• Behrends CN, Nugent AV, Des Jarlais DC, et al. Availability of HIV and HCV on-site testing and treatment at syringe service programs in the United States. J Acquir Immune Defic Syndr. 2018;79(2):e76–e78. doi: 10.1097/QAI.0000000000001792
   PubMed Web of Science ®Google Scholar
• Oldfield BJ, Muñoz N, Boshnack N, et al. “No more falling through the cracks”: a qualitative study to inform measurement of integration of care of HIV and opioid use disorder. J Subst Abuse Treat. 2019 Feb 01;97:28–40. doi: 10.1016/j.jsat.2018.11.007
   PubMed Web of Science ®Google Scholar
• Tofighi B, Sindhu SS, Chemi C, et al. Perspectives on the HIV continuum of care among adult opioid users in New York City: a qualitative study. Harm Reduct J. 2019 Oct 12;16(1):58. doi: 10.1186/s12954-019-0329-z
   PubMed Web of Science ®Google Scholar
• Otiashvili D, Piralishvili G, Sikharulidze Z, et al. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior—outcomes of a randomized trial. Drug Alcohol Depend. 2013 Dec 01;133(2):376–382. doi: 10.1016/j.drugalcdep.2013.06.024
   PubMed Web of Science ®Google Scholar
• Gowing LR, Farrell M, Bornemann R, et al. Brief report: methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med. 2006;21(2):193–195. doi: 10.1007/s11606-006-0258-x
   PubMed Web of Science ®Google Scholar
• Blue TR, Gordon MS, Schwartz RP, et al. Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine. Addict Sci Clin Pract. 2019 Dec 02;14(1):45. doi: 10.1186/s13722-019-0172-2
   PubMed Web of Science ®Google Scholar
• Woody GE, Bruce D, Korthuis PT, et al. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):288–293. doi: 10.1097/QAI.0000000000000165
   PubMed Web of Science ®Google Scholar
• Page K, Tsui J, Maher L, et al. Biomedical HIV prevention including pre-exposure prophylaxis and opiate agonist therapy for women who inject drugs: state of research and future directions. J Acquir Immune Defic Syndr. 2015 Jun 1;69 Suppl 2(1):S169–75. doi: 10.1097/QAI.0000000000000641
   PubMedGoogle Scholar
• Streed CG Jr., Morgan JR, Gai MJ, et al. Prevalence of HIV preexposure prophylaxis prescribing among persons with commercial insurance and likely injection drug use. JAMA Netw Open. 2022 Jul 1;5(7):e2221346. doi: 10.1001/jamanetworkopen.2022.21346
   PubMed Web of Science ®Google Scholar
• Adams JW, Marshall BDL, Salleh NAM, et al. Receipt of opioid agonist treatment halves the risk of HIV-1 RNA viral load rebound through improved ART adherence for HIV-infected women who use illicit drugs. Drug Alcohol Dependence. 2020;206:107670. doi: 10.1016/j.drugalcdep.2019.107670
   PubMed Web of Science ®Google Scholar
• Giang V, Brar R, Sutherland C, et al. HIV treatment initiation and retention among individuals initiated on injectable opioid agonist therapy for severe opioid use disorder: a case series. J Addict Med. 2020 Sep;14(5):437–440. doi: 10.1097/ADM.0000000000000609
   PubMed Web of Science ®Google Scholar
• National Academies of Sciences, Engineering, and Medicine. Opportunities to Improve Opioid Use Disorder and Infectious Disease Services: Integrating Responses to a Dual Epidemic. Washington (DC): The National Academies Press; 2020. doi: 10.17226/25626
   Google Scholar
• Goedel WC, Shapiro A, Cerdá M, et al. Association of racial/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States. JAMA Netw Open. 2020;3(4):e203711–e203711. doi: 10.1001/jamanetworkopen.2020.3711
   PubMed Web of Science ®Google Scholar
• Korthuis PT, Saha S, Fleishman JA, et al. Impact of patient race on patient experiences of access and communication in HIV care. J Gen Intern Med. 2008;23(12):2046–2052. doi: 10.1007/s11606-008-0788-5
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Slavova S, Root ED, et al. Disparities in opioid overdose death trends by race/ethnicity, 2018–2019, from the HEALing communities study. Am J Public Health. 2021;111(10):1851–1854. doi: 10.2105/AJPH.2021.306431
   PubMed Web of Science ®Google Scholar
• Lillie KM, Shaw J, Jansen KJ, et al. Buprenorphine/Naloxone for opioid use disorder among Alaska native and American Indian people. J Addict Med. 2021 Jul 1;15(4):297–302. doi: 10.1097/ADM.0000000000000757
   PubMed Web of Science ®Google Scholar
• Lagisetty PA, Ross R, Bohnert A, et al. Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry. 2019 Sep 1;76(9):979–981. doi: 10.1001/jamapsychiatry.2019.0876
   PubMed Web of Science ®Google Scholar
• Lynch ST, Katkhuda F, Klepacz L, et al. Racial disparities in opioid use disorder and its treatment: a review and commentary on the literature. J Ment Health Clin Psychol. 2023;7(1):13–18. doi: 10.29245/2578-2959/2023/1.1263
   Google Scholar
• Adams JW, Lurie MN, King MRF, et al. Potential drivers of HIV acquisition in African-American women related to mass incarceration: an agent-based modelling study. BMC Public Health. 2018 Dec 18;18(1):1387. doi: 10.1186/s12889-018-6304-x
   PubMedGoogle Scholar
• Westergaard RP, Kirk GD, Richesson DR, et al. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clinical Infectious Diseases. 2011;53(7):725–731. doi: 10.1093/cid/cir491
   PubMed Web of Science ®Google Scholar
• Tarfa A, Pecanac K, Shiyanbola OO. A qualitative inquiry into the patient-related barriers to linkage and retention in HIV care within the community setting. Explor Res Clin Soc Pharm. 2023 Mar;9:100207. doi: 10.1016/j.rcsop.2022.100207
   PubMedGoogle Scholar
• Alford DP, LaBelle CT, Richardson JM, et al. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med. 2007 Feb 01;22(2):171–176. doi: 10.1007/s11606-006-0023-1
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Needleman J, Gelberg L, et al. Association between homelessness and opioid overdose and opioid-related hospital admissions/emergency department visits. Soc Sci Med. 2019 Dec 01;242:112585. doi: 10.1016/j.socscimed.2019.112585
   PubMed Web of Science ®Google Scholar
• Danielson CK, McCauley J, Hinkley J, et al. Prevention and intervention with young people as a critical public health strategy to curtail the opioid epidemic: a call to action. J Addict Res Ther. 2023;14(4).
   Google Scholar
• Springer SA, Nijhawan AE, Knight K, et al. Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons. BMC Infect Dis. 2022 Apr 15;22(1):380. doi: 10.1186/s12879-022-07354-x
   PubMed Web of Science ®Google Scholar
• Hill K, Kuo I, Shenoi SV, et al. Integrated care models: HIV and substance use. Curr HIV/AIDS Rep. 2023 Oct;20(5):286–295. doi: 10.1007/s11904-023-00667-9
   PubMed Web of Science ®Google Scholar
• Legislature C. Substitute senate bill No. 1102, public act No. 23-19. AN ACT Concern PHARMACIES PHARMACISTS. 2023.
   Google Scholar
• DiPaula BA, Cooke CE. Assessing suboxone access in community pharmacies: Secret shopper model. Explor Res In Clin And Soc Pharm. 2023 Dec 01;12:100356. doi: 10.1016/j.rcsop.2023.100356
   PubMedGoogle Scholar
• Mullen W, Hedberg M, Gadbois B, et al. The introduction of a novel formulation of buprenorphine into organized health systems. Drug Alcohol Depend Rep. 2022 Sep;4:10009. doi: 10.1016/j.dadr.2022.100090
   Google Scholar